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Fibromyalgia is “a painful musculoskeletal disorder characterized by widespread
chronic pain as a core clinical feature associated with fatigue, non-refreshed
sleep, and morning stiffness in more than 75% of cases, paraesthesia, irritable
bowel syndrome, functional disability in 25% of cases”. This definition poses
a clinical misunderstanding and a pathophysiologic challenge as in “fibromyal-
gia”, the emphasis is focused on the muscle and on pain. This may lead many
doctors to consider the muscle as a treatment target. On the other side, its patho-
physiology is still a challenge even if several lines of research using both invasive
and non-invasive methodology assess a substantial integrity of the fibromyalgic
muscle. Moreover, several data confirm the presence of a central sensitization
posing fibromyalgia within the so-called central sensitization syndromes (CSS).
CSS are mediated by the central nervous system. Fibromyalgia and CCS are
clinically and physiologically characterized by: hyperalgesia (excessive sensi-
tivity to a normally painful stimulus), allodynia (painful sensation to a normally
non-painful stimulus), expansion of the receptive field (pain beyond the area
of peripheral nerve supply), prolonged electrophysiological discharge, and an
after-stimulus unpleasant quality of pain (e.g., burning, throbbing, tingling or
numbness). As to say in fibromyalgia: more brain than muscle.
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Pharmacological treatment in the fibromyalgia syndrome (FMS) is part of the
multimodal approach needed in this condition, but there is no evidence that
patients experience harm if they do not receive drugs. All drugs that have been
proven effective in randomized controlled clinical trials have, on average, low
effect sizes, which means that the gain in pain reduction, improvement of sleep,
depression or other fibromyalgia symptoms is mild to moderate compared to
a placebo treatment [1]. Nevertheless, drug treatment should not be withheld
from patients and should be administered using a shared-decision strategy. Treat-
ment should be adapted to an individual patient’s symptoms taking into account
co-morbidities and potential side effects. A drug should only be continued in
responders. At present, pregabalin, duloxetine, milnacipran and amitriptyline
are the current first-line agents. Recent data showing nociceptor pathology in
FMS patients [2] may explain the overlap of drugs used in FMS with those used
against neuropathic pain.
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During the past decades, the approach to treat patients with fibromyalgia was
sustained by osteoarticular theories; the Physical Rehabilitation and Medicine
(PRM) physician tried to support their patients using physical therapy according
attention to the tendons, the joints and/or the muscle.
Then, we considered the aerobic conditions of patients with fibromyalgia and
created programs with land- or water-based aerobic physical activity. At this
stage, the PRM physician was considered like a cardiologist, a physiologist or
a personal trainer.
Within the last 3 years, many studies confirmed our impression that the leading
cause for fibromyalgia was probably located in the brain and involved many
processes, like immunologic-modulation, pain-modulation, cardiorespiratory
dysfunction.
In consequence, the PRM physician tends to become a new super doctor with
superpowers, treating the muscle, the heart, the lungs and also – what a supreme
consecration – the whole brain with his so complex mechanisms.
A new era is opened for the physical medicine and rehabilitation with an evolu-
tion from the muscle to the brain, using aerobic exercise, Tai Chi, Nordic walking,
Spa therapy or acupuncture. The condition for success is to treat and follow our
patient for a long time and within an individually customized program.
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